Literature DB >> 22445095

The PI3K/AKT/mTOR signalling pathway is active in salivary gland cancer and implies different functions and prognoses depending on cell localisation.

Tobias Ettl1, Stephan Schwarz-Furlan, Frank Haubner, Steffen Müller, Johannes Zenk, Martin Gosau, Torsten E Reichert, Katharina Zeitler.   

Abstract

OBJECTIVES: The PI3K/AKT/mTOR signalling axis controls cell proliferation and survival and has achieved major importance as a target for cancer therapy. This investigation evaluated the expression of the major components P-AKT, P-mTOR, PI3K and P-S6rp in salivary gland cancer.
MATERIALS AND METHODS: Immunohistochemical expression of P-AKT, P-mTOR, PI3K and P-S6rp was evaluated and correlated to clinicopathological parameters and survival of 272 patients with salivary gland carcinomas. RESULTS AND
CONCLUSION: Analysis of all tumours together revealed an increased expression of all components of the pathway in comparison to normal salivary gland control tissue. Nuclear expression of P-AKT was associated with young age, localised tumour stage, absence of lymph node metastases and favourable prognosis. On the contrary, cytoplasmic P-AKT displayed unfavourable tumour characteristics like high-grade malignancy, and worse overall survival. In comparison to cytoplasmic/membrane mTOR expression, nuclear P-mTOR was associated with absence of lymph node metastases and higher survival rates. PI3K and P-S6rp were exclusively found in the cytoplasm. Expression of P-S6rp was correlated to increased age, advanced tumour size and lymph node metastases. In all tumours together, nuclear P-AKT positively correlated with nuclear P-mTOR, whereas P-S6rp was associated with expression of PI3K and cytoplasmic P-AKT. In acinic cell carcinoma, cytoplasmic expression of P-AKT, P-mTOR, PI3K and P-S6rp was positively associated with each other. In conclusion, PI3K/AKT/mTOR signalling is active in salivary gland cancer and might function as a target for personalised therapy. P-AKT and P-mTOR possess distinct molecular functions with impact on prognosis depending on their cellular localisation.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22445095     DOI: 10.1016/j.oraloncology.2012.02.021

Source DB:  PubMed          Journal:  Oral Oncol        ISSN: 1368-8375            Impact factor:   5.337


  16 in total

Review 1.  Salivary acinic cell carcinoma: reappraisal and update.

Authors:  V Vander Poorten; A Triantafyllou; L D R Thompson; J Bishop; E Hauben; J Hunt; A Skalova; G Stenman; R P Takes; D R Gnepp; H Hellquist; B Wenig; D Bell; A Rinaldo; A Ferlito
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-12-19       Impact factor: 2.503

2.  Predictive value of FHIT, p27, and pERK1/ERK2 in salivary gland carcinomas: a retrospective study.

Authors:  Mathias Fiedler; Patty Renner; Jürgen Schubert; Florian Weber; Arndt Hartmann; Heinrich Iro; Veronika Vielsmeier; Christopher Bohr; Michael Gerken; Torsten E Reichert; Tobias Ettl
Journal:  Clin Oral Investig       Date:  2019-01-23       Impact factor: 3.573

3.  Inactivation of the LKB1-AMPK signaling pathway does not contribute to salivary gland tumor development - a short report.

Authors:  Natascha Cidlinsky; Giada Dogliotti; Tobias Pukrop; Rudolf Jung; Florian Weber; Michael P Krahn
Journal:  Cell Oncol (Dordr)       Date:  2016-08-01       Impact factor: 6.730

Review 4.  A review: Immunological markers for malignant salivary gland tumors.

Authors:  P C Anila Namboodiripad
Journal:  J Oral Biol Craniofac Res       Date:  2014-08-28

Review 5.  Salivary gland carcinomas.

Authors:  Tobias Ettl; Stephan Schwarz-Furlan; Martin Gosau; Torsten E Reichert
Journal:  Oral Maxillofac Surg       Date:  2012-07-29

6.  High frequency of loss of PTEN expression in human solid salivary adenoid cystic carcinoma and its implication for targeted therapy.

Authors:  Han Liu; Li Du; Ru Wang; Chao Wei; Bo Liu; Lei Zhu; Pixu Liu; Qiang Liu; Jiang Li; Shi-Long Lu; Jing Xiao
Journal:  Oncotarget       Date:  2015-05-10

7.  miR-1236 down-regulates alpha-fetoprotein, thus causing PTEN accumulation, which inhibits the PI3K/Akt pathway and malignant phenotype in hepatoma cells.

Authors:  Rui Gao; Chunli Cai; Jiancheng Gan; Xi Yang; Zeyu Shuang; Min Liu; Shengping Li; Hua Tang
Journal:  Oncotarget       Date:  2015-03-20

8.  Immunohistochemical analysis of salivary gland tumors: application for surgical pathology practice.

Authors:  Toshitaka Nagao; Eiichi Sato; Rie Inoue; Hisashi Oshiro; Reisuke H Takahashi; Takeshi Nagai; Maki Yoshida; Fumie Suzuki; Hiyo Obikane; Mitsumasa Yamashina; Jun Matsubayashi
Journal:  Acta Histochem Cytochem       Date:  2012-09-22       Impact factor: 1.938

9.  Autocrine activity of BDNF induced by the STAT3 signaling pathway causes prolonged TrkB activation and promotes human non-small-cell lung cancer proliferation.

Authors:  Bo Chen; Yan Liang; Zheng He; Yunhe An; Weihong Zhao; Jianqing Wu
Journal:  Sci Rep       Date:  2016-07-26       Impact factor: 4.379

10.  Prognostic and histogenetic roles of gene alteration and the expression of key potentially actionable targets in salivary duct carcinomas.

Authors:  Tomotaka Shimura; Yuichiro Tada; Hideaki Hirai; Daisuke Kawakita; Satoshi Kano; Kiyoaki Tsukahara; Akira Shimizu; Soichiro Takase; Yorihisa Imanishi; Hiroyuki Ozawa; Kenji Okami; Yuichiro Sato; Yukiko Sato; Chihiro Fushimi; Hideaki Takahashi; Takuro Okada; Hiroki Sato; Kuninori Otsuka; Yoshihiro Watanabe; Akihiro Sakai; Koji Ebisumoto; Takafumi Togashi; Yushi Ueki; Hisayuki Ota; Mizuo Ando; Shinji Kohsaka; Toyoyuki Hanazawa; Hideaki Chazono; Yoshiyuki Kadokura; Hitome Kobayashi; Toshitaka Nagao
Journal:  Oncotarget       Date:  2017-12-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.